Description
Theoritin-MF Pharmacodynamics
Theoritin® MF (3-methyl-7-[4-(4-benzhydrylpiperazinyl-1)butyl] xanthine succinate) is a purine derivative with strong anti-allergic activity, associated with prolonged and selective blockade of H1 -histamine receptors, Theoritin® MF prevents and relieves allergic reactions. It has antipruritic and antiexudative effects. It has weak m-cholinoblocking and antiserotonin activity. It does not have sedative properties and does not affect the speed of psychomotor reactions. It is superior in activity and duration of antihistamine action as compared to first generation H1-histamine blockers – diphenhydramine, chifenadine and azelastine and second generation cetirizine, loratadine, fexofenadine, which was demonstrated on experimental model of Theoritin® MF effect on histamine spasmogenic action in guinea pig isolated ileum. Theoritin® MF is close to azelastine in its antiserotonin activity, which determines the antipruritic effect of this group of drugs and significantly exceeds the other drugs listed above.
Indications
Symptomatic treatment – chronic idiopathic urticaria, seasonal allergic rhinitis.
Contraindications
-High sensitivity to the active substance or any other
component of the drug.
-Pregnancy and period of breast-feeding;
-Children under 18 years of age.
-Renal, hepatic failure.
Caution
Closed-angle glaucoma, prostatic hyperplasia.
Elderly age.
Administration during pregnancy and breast feeding.
Administration of Theoritin® MF is contraindicated in pregnancy and during breast feeding.
Dosage and administration administration
- Orally, 4 mg once a day. It is desirable to take the drug in the morning, at the same time.
- The duration of the course of treatment is 14 days.
